The changing landscape of molecular radiotherapy
Radionuclide therapy is probably the only field of medicine that allows direct imaging of a drug as it is used to treat cancer. Radioiodine was first used over 70 years ago for the treatment of benign thyroid disease and thyroid cancer. Levels of activity to administer were determined empirically, influenced largely by limitations in supply from newly commissioned cyclotrons. After many decades of little growth, a dramatic increase in radiotherapeutics now heralds what is promising to be a step change in this area of cancer management. Significant changes are being seen in terms of the products available, the costs associated with these products, treatment regimens and regulations.
The content on this page is provided by the individuals concerned and does not represent the views or opinions of RAD Magazine.


